Coleus forskohlii (Forskolin)
Coleus forskohlii is a plant in the mint family whose root contains forskolin, a compound that raises the cell messenger cyclic AMP in lab studies. Supplements use root extract standardized to forskolin, most often 10%. It is marketed for weight loss, but the human evidence is four small 12-week trials with mixed results. One trial in 30 overweight men reported less body fat on scans than placebo, while trials in women and in dieting adults found no difference in weight or body fat; a newer trial run partly by researchers at the extract's maker reported about 1 kg more weight loss than placebo. No trial has shown lasting weight loss. Lab and animal studies suggest forskolin and the extract can affect blood pressure, platelets and liver drug-processing enzymes, so anyone on blood pressure medicines or blood thinners should ask a doctor first. Loose stools were the side effect reported in trials.
Benefits
Body fat measured by DXA scan in overweight men
In a 12-week placebo-controlled trial in 30 overweight and obese men, 250 mg of a 10% forskolin extract twice daily lowered body fat percentage and fat mass on DXA scans compared with placebo; the rise in lean mass was only a trend. This is one small trial, and the same dose did not change body fat in women or in dieting adults.
Body composition and appetite ratings in overweight women
In a 12-week double-blind trial in mildly overweight women taking ForsLean at the same dose, fat mass and body fat did not differ from placebo. The extract group tended to gain less weight and reported less hunger and fullness. Results were reported for only 19 women, and the authors concluded the extract does not appear to promote weight loss.
Body weight and waist size in a 60-adult trial
In a 12-week placebo-controlled trial in 60 overweight adults, most of them women, the extract group lost about 1.9 kg and 1.8 cm of waist versus about 1.0 kg and 1.0 cm on placebo. Allocation was quasi-random rather than truly random, two authors work for the extract's maker, and the tables contain errors, so the result is uncertain.
Insulin levels alongside a reduced-calorie diet
In a 12-week placebo-controlled trial in 30 overweight adults who were all following a reduced-calorie diet, fasting insulin and an insulin-resistance score improved more with the extract than with placebo. Fasting blood sugar, weight and waist did not differ between groups, and on one diet questionnaire the extract group reported eating less. This is a single small trial.
Free testosterone in overweight men
In the same 30-man trial that reported lower body fat, serum free testosterone rose compared with placebo, but total testosterone did not differ significantly between groups. A later systematic review of herbs and testosterone found only some evidence for this root extract. The finding has not been repeated in another trial.
Mechanism of action
Raises cyclic AMP in cells
Forskolin switches on adenylyl cyclase, the enzyme that makes the cell messenger cyclic AMP. In fat cells in the lab, more cyclic AMP is linked to fat breakdown, which is the idea behind its weight-loss marketing. Trials have not shown that oral doses produce this effect in a way that leads to lasting weight loss.
Speeds up liver drug-processing enzymes in animals
In mice, the whole root extract increased liver enzymes that break down drugs, including the CYP2C enzyme that clears warfarin, and switched on the CYP3A4 gene in cell tests. In ordinary mice pure forskolin had much weaker effects than the extract, but in mice given human-type drug metabolism forskolin itself raised CYP3A4 gene activity. This has not been measured in people.
Reduces platelet clumping in the lab
In human platelet samples in the test tube, forskolin reduced platelet aggregation, and some prescription drugs strengthened the effect. Whether supplement doses do this in the body is unknown, but it is the basis for bleeding cautions.
Clinical trials
Randomized, double-blind, placebo-controlled trial of 250 mg Coleus forskohlii extract (10% forskolin) twice daily for 12 weeks, measuring body composition by DXA, testosterone, metabolic rate and blood pressure (Godard et al. 2005, Obes Res)
30 overweight and obese men with BMI of 26 or more (15 extract, 15 placebo).
Body fat percentage and fat mass fell significantly versus placebo and bone mass changed versus placebo. Lean mass rose only as a trend (p = 0.097). Free testosterone rose versus placebo; total testosterone changes (+16.8% vs -1.1%) were not significantly different. A small, single trial.
Double-blind randomized placebo-controlled trial of ForsLean, 250 mg of 10% extract twice daily for 12 weeks, measuring DXA body composition, blood safety markers and side effects (Henderson et al. 2005, J Int Soc Sports Nutr)
23 mildly overweight women enrolled; results reported for 7 on the extract and 12 on placebo.
No significant differences in fat mass (p = 0.16), fat-free mass or body fat percentage (p = 0.40). The extract group tended to gain less weight (p = 0.10) and reported less hunger and fullness. No clinically significant changes in blood tests, thyroid hormones, heart rate or blood pressure. The authors concluded it does not appear to promote weight loss.
Randomized, double-blind, placebo-controlled trial of 250 mg extract (10% forskolin) twice daily before meals for 12 weeks, with all participants advised to eat about 500 kcal a day less; the extract and placebo were made and supplied by Olive Life Sciences, India (Loftus et al. 2015, Nutrients)
41 overweight or obese adults enrolled in Australia; 30 completed (24 women, 6 men).
Weight, BMI and other body measurements did not differ from placebo; waist, hip and HDL changes occurred in both groups, likely from the diet. Fasting insulin (p = 0.001) and insulin resistance (p = 0.01) improved versus placebo, while fasting blood sugar did not change. Two people on the extract had loose stools or more frequent bowel movements in the first three weeks.
Double-blind, placebo-controlled, quasi-randomized trial of 250 mg Coleus forskohlii extract (10% forskolin, Forcslim) twice daily before meals for 12 weeks on participants' usual diet (Channangihalli Thimmegowda et al. 2026, J Int Soc Sports Nutr)
60 overweight adults aged 20 to 70 in India (30 per group), mostly women.
Per the paper's tables, weight fell about 1.9 kg with the extract versus about 1.0 kg with placebo, and waist about 1.8 cm versus 1.0 cm; the authors report these differences as significant. Liver enzymes stayed within normal ranges, blood pressure and heart rate did not differ from placebo, and no adverse events were reported. The tables are internally inconsistent, and a pairwise group comparison listed for weight and waist was not significant. Allocation was not truly random. Two authors work in research and development at the maker, Star Hi Herbs, which prepared the product, yet the paper declares no funding and no conflict of interest. A correction has been published.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Coleus forskohlii (Forskolin)
Will Coleus forskohlii help me lose weight?
The evidence does not support it as a weight-loss aid. Four small 12-week trials gave mixed results: less body fat on scans in 30 men, no change in women or in adults on a diet, and about 1 kg more weight loss than placebo in a trial run partly by researchers at the extract's maker. Reviews of weight-loss supplements found no clear evidence of lasting weight loss.
How is this different from ForsLean?
ForsLean is a branded Coleus forskohlii root extract standardized to 10% forskolin, and it was the product named in the trial in women. The other trials used 10% extracts at the same dose. See our ForsLean page for the branded ingredient.
Is forskolin safe for the liver?
Human trials of up to 12 weeks found no clinically meaningful changes in liver enzymes. In mice, however, the whole root extract enlarged the liver and raised liver enzymes, apparently because of compounds other than forskolin, and it sped up enzymes that process many drugs. Use the studied dose, avoid stacking it with other slimming products, and stop if you notice signs of liver trouble.
Can I take it with blood pressure medicine or a blood thinner?
Only with your doctor's agreement. Forskolin lowers blood pressure and reduces platelet clumping in lab studies, and in mice the extract changed how warfarin was cleared. How much this matters in people has not been tested.
What is Coleus forskohlii?
Coleus forskohlii is a plant in the mint family whose root contains forskolin, a compound that raises the cell messenger cyclic AMP in lab studies. Supplements use root extract standardized to forskolin, most often 10%.
What is Coleus forskohlii used for?
Coleus forskohlii is researched primarily for Weight Management and Metabolic Health. In a 12-week placebo-controlled trial in 30 overweight and obese men, 250 mg of a 10% forskolin extract twice daily lowered body fat percentage and fat mass on DXA scans compared with placebo; the rise in lean mass was only a trend.
What is the recommended dosage of Coleus forskohlii?
The clinically studied dose is 250 mg of root extract standardized to 10% forskolin, taken twice daily (500 mg extract, 50 mg forskolin a day), usually 30 minutes before meals, for 12 weeks. This was the dose in all four weight trials; longer use has not been studied. Always follow the product label and check with a healthcare provider for personal advice.
Does Coleus forskohlii interact with any medications?
Possible interactions include: Blood pressure medicines (beta-blockers, ACE inhibitors, calcium channel blockers, vasodilators): possible added blood pressure lowering; check with your doctor. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Coleus forskohlii?
NutraSmarts rates the evidence for Coleus forskohlii as Limited (2 out of 5). It is backed by 4 study summaries and 13 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(13 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res. 2005;13(8):1335-43. doi: 10.1038/oby.2005.162.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 30 overweight and obese men (15 per group) given 250 mg of a 10% forskolin extract twice daily for 12 weeks. Body fat percentage and fat mass measured by DXA fell significantly versus placebo, bone mass changed versus placebo, and serum free testosterone rose versus placebo. The rise in lean mass was only a trend (p = 0.097), and total testosterone did not differ significantly between groups.
- Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J Int Soc Sports Nutr. 2005;2(2):54-62. doi: 10.1186/1550-2783-2-2-54.PubMedUsed to support: Double-blind randomized trial in mildly overweight women (23 enrolled; results reported for 7 on ForsLean 250 mg of 10% extract twice daily and 12 on placebo) over 12 weeks. No significant differences in fat mass, fat-free mass or body fat; the extract group tended to gain less weight and reported less hunger and fullness. No clinically significant changes in blood tests, thyroid hormones, heart rate, blood pressure or side effects. The authors concluded it does not appear to promote weight loss.
- Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial. Nutrients. 2015;7(11):9508-22. doi: 10.3390/nu7115483.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in overweight and obese adults on a reduced-calorie diet (41 enrolled, 30 completed, 80% women): 250 mg of extract standardized to 10% forskolin twice daily for 12 weeks. Weight and body measurements did not differ from placebo; waist, hip and HDL changes occurred in both groups. Fasting insulin and insulin resistance improved versus placebo. Two people on the extract reported loose stools or more frequent bowel movements. The extract and placebo were made and supplied by Olive Life Sciences, India.
- A 12-week, double-blind, quasi-randomized, placebo-controlled study to evaluate the efficacy and safety of Coleus forskohlii (Forcslim) on body weight loss. J Int Soc Sports Nutr. 2026;23(1):2725137. doi: 10.1080/15502783.2026.2725137.PubMedUsed to support: Quasi-randomized (not truly randomized), double-blind, placebo-controlled trial in 60 overweight adults, most of them women, given 250 mg of a 10% forskolin extract (Forcslim) twice daily before meals for 12 weeks on their usual diet. Per the paper's tables, the extract group lost about 1.9 kg and 1.8 cm of waist versus about 1.0 kg and 1.0 cm on placebo, differences the authors report as significant. Liver enzymes stayed within normal ranges, blood pressure and heart rate did not differ from placebo, and no adverse events were reported; the tables are internally inconsistent. Two authors work in research and development at the extract's maker, Star Hi Herbs, which prepared the product, yet the paper declares no funding and no conflict of interest; a correction has been published.
- Examining the Effects of Herbs on Testosterone Concentrations in Men: A Systematic Review. Adv Nutr. 2021;12(3):744-765. doi: 10.1093/advances/nmaa134.PubMedUsed to support: Systematic review of 32 randomized trials of 13 single herbs on testosterone in men. It found positive effects for fenugreek and ashwagandha and described only some evidence for forskohlii root extract and Asian red ginseng, noting small samples, varied extracts and few low-risk-of-bias studies.
- The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Crit Rev Food Sci Nutr. 2020;60(10):1614-1630. doi: 10.1080/10408398.2019.1584873.PubMedUsed to support: Critical review of ten commonly marketed weight-loss supplements, including Coleus forskohlii, in people with obesity. It found insufficient evidence that the supplements examined produce meaningful weight loss (with the possible exception of one glucomannan product); side effects were mostly minor to moderate and digestive, with rare serious liver or kidney harm across the group.
- Evidence for the efficacy and safety of herbal weight loss preparations. J Integr Med. 2019;17(2):87-92. doi: 10.1016/j.joim.2019.01.009.PubMedUsed to support: Literature review of five herbs common in weight-loss products, including Coleus forskohlii. It found no clear evidence of sustained long-term weight loss in humans, few clinical trials, and little attention to herb-drug interactions.
- Dietary Coleus forskohlii extract generates dose-related hepatotoxicity in mice. J Appl Toxicol. 2013;33(9):924-32. doi: 10.1002/jat.2770.PubMedUsed to support: Mouse study: diets containing a 10% forskolin Coleus forskohlii extract caused dose-related liver enlargement, raised liver enzymes (AST, ALT, ALP) and fat deposits in liver cells. Liver weight and enzymes returned toward normal within a week of stopping. Pure forskolin at the matching dose did not, pointing to other constituents of the extract. Animal data only.
- Coleus forskohlii extract induces hepatic cytochrome P450 enzymes in mice. Food Chem Toxicol. 2012;50(3-4):750-5. doi: 10.1016/j.fct.2011.11.054.PubMedUsed to support: Mouse study: a 10% forskolin Coleus forskohlii extract increased liver drug-metabolizing (cytochrome P450 and GST) enzymes within a week, effects that recovered after stopping. Pure forskolin had only weak effects, so other constituents of the extract were mainly responsible. Animal data suggesting a potential for drug interactions.
- Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro. J Pharm Pharmacol. 2012;64(12):1793-801. doi: 10.1111/j.2042-7158.2012.01563.x.PubMedUsed to support: Mouse and liver-enzyme study: Coleus forskohlii extract induced the liver enzyme CYP2C and weakened the blood-thinning effect of warfarin in mice. The authors advise caution when combining warfarin with supplements containing the extract. Not tested in people.
- Exploring Acute Liver Damage: Slimming Health Foods and CYP3A4 Induction. Yonago Acta Med. 2024;67(2):124-134. doi: 10.33160/yam.2024.05.004.PubMedUsed to support: Laboratory and mouse study prompted by patients who developed acute liver injury while taking several drugs and slimming health foods. Coleus forskohlii extract strongly switched on the CYP3A4 drug-metabolizing gene in cell tests, and forskolin raised CYP3A4 gene expression in mice engineered with human-type drug metabolism. The authors propose this as one possible route to liver injury, for example with acetaminophen; it was not tested in people.
- Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Thromb Haemost. 1989;61(1):106-10..PubMedUsed to support: Laboratory study in human and rat platelet-rich plasma: forskolin inhibited platelet aggregation, and the effect was strongly amplified by the prescription drugs dipyridamole and dilazep. Test-tube data, not a study of people taking the supplement.
- Forskolin (Coleus forskohlii). Memorial Sloan Kettering Cancer Center. 2023;Integrative Medicine, About Herbs monograph, last updated June 2, 2023..SourceUsed to support: Not PubMed-indexed; a clinical herb monograph read on its website. It lists low blood pressure, fast heart rate, headache and digestive symptoms including diarrhea as reported adverse effects; notes that lab experiments show blood-pressure lowering and platelet inhibition; flags possible interactions with blood pressure medicines and blood thinners such as warfarin (clinical relevance not yet determined); cautions people with polycystic kidney disease; and states that clinical studies showing safety and effectiveness are lacking.